Pharmaceutical Sourcing for Africa: 2026 Buyer's Guide

By the PharmaTradz BD Team. Updated October 2026.

Africa imports most of the finished medicines and almost all of the active pharmaceutical ingredients (APIs) it uses. Local production is growing, but importers, distributors, hospital groups and central medical stores still build their portfolios from several supply bases at once. Getting the mix right, and getting it registered, is most of the work.

This guide is written for buyers who source for one or more African markets. It covers where products come from, how registration works now that the African Medicines Agency is up and running, how to qualify a supplier, how public tenders work, and what to plan for in logistics.

It also works as the hub for our country guides. If you buy for a specific market, jump to the country guide directory near the end.

Where Africa's medicines come from

No single country supplies the continent. A realistic picture looks like this:

Local and regional manufacturers. North Africa (Egypt, Morocco, Algeria, Tunisia) and South Africa have established formulation industries. Kenya, Nigeria, Ghana and Ethiopia have growing local production, mostly in oral solids, liquids and some IV fluids. Most local plants still rely on imported APIs and excipients.
India and China. India is a major source of finished generics, including many WHO-prequalified HIV, TB and malaria products. China is the largest source of APIs, intermediates and many excipients, and a growing source of finished products and medical consumables.
Europe and the United States. These remain the main sources for complex, sterile, biologic and specialty products: vaccines, insulin and other biologics, oncology, rare-disease medicines and many hospital injectables.
Other bases. Turkey, the Gulf states, South Korea and parts of Southeast Asia also supply generics, injectables and consumables, especially into North and East Africa.

Most experienced buyers deliberately keep at least two qualified sources for high-volume or tender-critical molecules, often from different regions. That is the simplest protection against a plant inspection finding, an API shortage or a shipping disruption.

What African buyers typically source

Essential medicines: antibiotics, analgesics, antimalarials, antiretrovirals, TB medicines and paediatric formulations.
Chronic disease therapy: diabetes, hypertension, cardiovascular and gastrointestinal medicines, where demand is rising fast in urban markets.
Hospital products: IV fluids, sterile injectables, anaesthetics, oncology injectables and sterile injectable contract manufacturing for tender or private-label supply.
APIs and intermediates for local formulators. Our API suppliers page explains what to ask for.
Contract manufacturing for distributors building their own brands, from tablet contract manufacturing to oral liquids.
OTC products, nutraceuticals and hospital disposables.

Regulators and registration across Africa

Every country still has its own national medicines regulatory authority (NMRA), and the national marketing authorisation is what lets you sell. Examples include NAFDAC in Nigeria, SAHPRA in South Africa, the Pharmacy and Poisons Board in Kenya, the Food and Drugs Authority in Ghana, the Egyptian Drug Authority and TMDA in Tanzania. What has changed is how much work the regulators now share.

AMRH: the harmonisation groundwork

The African Medicines Regulatory Harmonisation (AMRH) initiative is an African Union programme, launched in 2009, with AUDA-NEPAD and WHO as its joint secretariat. It works through the regional economic communities to align guidelines, run joint dossier reviews and build regulator capacity. ZAZIBONA in southern Africa and the EAC joint assessment grew out of this work. Similar joint reviews are developing in West Africa through ECOWAS (via WAHO) and WAEMU, and in central Africa and the Horn.

The African Medicines Agency in 2026

The AMA treaty entered into force in 2021, and the agency is headquartered in Kigali, Rwanda. Its first Director General, Dr Delese Mimi Darko, took office in 2025, and more than 30 African Union member states have ratified the treaty. The AMA does not replace national regulators. It coordinates them and is focusing first on complex products, vaccines and products of public health importance, with technical committees covering assessment, inspections, clinical trials and safety. For routine generics, expect to keep registering country by country, using the regional routes below to save time.

ZAZIBONA (SADC)

ZAZIBONA started in 2013 with Zambia, Zimbabwe, Botswana and Namibia, and is now part of the SADC medicines registration harmonisation work. The active assessing members currently include Botswana, DR Congo, Malawi, Mozambique, Namibia, South Africa, Tanzania, Zambia and Zimbabwe. You submit the same dossier and pay fees in each country you target. A rapporteur and co-rapporteur assess it, the group agrees one list of questions and a recommendation, and each country then makes its own registration decision.

EAC joint assessment

The East African Community joint assessment procedure brings together the regulators of Burundi, Kenya, Rwanda, South Sudan, Tanzania (mainland and Zanzibar) and Uganda. One dossier is assessed jointly, often with a joint GMP inspection, and the EAC issues a recommendation. You then apply nationally, and partner states aim to decide within a set period. National registration is still required, so budget for local fees and labelling.

WHO collaborative registration procedure

If your product is WHO-prequalified, or approved by a WHO-listed or stringent regulatory authority, the WHO collaborative registration procedure (CRP) lets participating African regulators rely on the existing assessment and inspection reports. The target is a national decision within 90 working days of receiving the full documentation. Many African NMRAs take part, and it is often the fastest route for prequalified HIV, TB, malaria and reproductive health products.

For help preparing files, see our dossier licensing and registration service.

How to qualify a supplier

Whatever the origin, the same checks apply. A clean paper trail is what gets a product through registration and a tender evaluation.

GMP certificate. Confirm the certificate is current, covers the actual site and dosage form, and was issued by a credible authority (WHO prequalification, a PIC/S member or a stringent regulator). Check it against the issuer's public database where one exists. Our guide on how to check a WHO-GMP certificate is genuine walks through this.
COPP. Most African regulators ask for a WHO-format Certificate of a Pharmaceutical Product. Check that it lists the right manufacturing site and states whether the product is marketed in the exporting country.
CoA and batch records. Ask for certificates of analysis for recent commercial batches, not just exhibit batches, and test samples locally when the regulator or tender requires it.
Stability for the right climatic zone. Most of sub-Saharan Africa requires Zone IVb data (30°C / 75% RH). Do not accept Zone II data for a hot, humid market.
Dossier format. CTD is the norm across ZAZIBONA, the EAC and most national authorities. Check whether the regulator wants English, French or Arabic, and whether it accepts eCTD.

For a fuller checklist, read how to verify a pharmaceutical supplier. If you are choosing a contract manufacturer, our CDMO buyer's hub covers capability and audit questions.

Public procurement and tenders

A large share of African medicine spending runs through public channels. Each one sets its own quality bar.

Central medical stores and national agencies, such as KEMSA in Kenya, the Medical Stores Department in Tanzania, National Medical Stores in Uganda and the Ethiopian Pharmaceutical Supply Service. They usually require national registration, or a waiver, before award.
Global Fund, UNICEF and other donor-funded programmes. These generally require WHO prequalification, approval by a stringent or WHO-listed authority, or a positive Expert Review Panel opinion for the product.
WHO prequalification itself, which is the entry ticket for most donor-funded HIV, TB, malaria, reproductive health and vaccine tenders.

Practical points: tenders often set short delivery windows, fixed labelling and specific pack sizes, and many charge penalties for late delivery. Price the full landed cost, including registration and freight. Browse open opportunities on our pharma tenders page, or see how we support government tender supply.

Logistics and cold chain into Africa

The main sea gateways are Durban, Mombasa, Dar es Salaam, Lagos, Tema, Abidjan, Dakar, Djibouti, Alexandria and Tanger Med. The main air hubs for pharma freight are Johannesburg, Nairobi, Addis Ababa, Cairo, Lagos and Accra. Landlocked markets such as Uganda, Rwanda, Zambia and Ethiopia are usually served overland from a coastal port.

Sea freight from South and East Asia typically takes three to six weeks to the main ports, depending on route and transhipment.
Sea freight from Europe typically takes one to three weeks to North Africa and two to five weeks to West, East and southern Africa.
Air freight typically takes three to seven days door to door, including clearance.
Inland transit from a port to a landlocked capital can typically add one to three weeks.

For vaccines, biologics and 2–8°C injectables, use temperature-qualified packaging, data loggers and a forwarder with proven GDP compliance on your lane. Plan for customs delays at the destination airport, which is where most temperature excursions happen. See our cold chain pharma logistics service and our guide to GDP rules and what to check.

Common problems and practical fixes

Problem	Practical fix
Registration takes longer than the commercial plan allows	Use ZAZIBONA, the EAC joint assessment or the WHO CRP where the product qualifies, and file in several countries at once.
Dossier rejected for stability data	Confirm Zone IVb long-term data before you sign. Ask for the stability protocol, not only the summary.
GMP certificate does not match the site or product	Verify the certificate with the issuing authority and match the site address to the COPP and labels.
Substandard or falsified product in the channel	Buy only from qualified sources, test samples on receipt and report suspect batches to the national regulator.
Single-source tender risk	Qualify a second source for every tender-critical molecule, ideally from a different region.
Temperature excursions on arrival	Book pre-cleared, temperature-controlled handling at the destination airport and use data loggers on every shipment.
Payment and currency risk	Use letters of credit or an advance plus balance against shipping documents, and agree the Incoterm and currency up front.

If you are dealing with a supply gap, our drug shortages tracker can help you find alternative sources.

Country guide directory

Use these guides for country-specific regulators, registration steps, tender channels and ports.

How we can help

PharmaTradz works with GMP-certified manufacturers and CDMOs across Asia, Europe, the Americas and Africa. Tell us the product, strength, target markets and the registration route you plan to use, and we will match you with suppliers whose documents fit. Send an RFQ to get started.

Frequently Asked Questions(FAQs)

Is the African Medicines Agency approving medicines in 2026?

The AMA is operational in Kigali and coordinates national regulators, with an early focus on complex products, vaccines and products of public health importance. For most generics, national registration is still required, and AMA benefits apply only in countries that have ratified its treaty.

Does a ZAZIBONA recommendation register my product in every SADC country?

No. ZAZIBONA produces a joint assessment and recommendation, but each country makes its own decision and charges its own fees. It does cut duplicated review work and usually shortens timelines.

Which East African countries take part in the EAC joint assessment?

The regulators of Burundi, Kenya, Rwanda, South Sudan, Tanzania (including Zanzibar) and Uganda. After a positive joint recommendation, you still file for national marketing authorisation in each partner state.

Which stability data do African regulators expect?

For most of sub-Saharan Africa, long-term stability data at Zone IVb conditions (30°C / 75% RH) is the safe default. Check the specific regulator's guideline before filing, especially for North African markets.

Can a WHO-prequalified product be registered faster in Africa?

Usually, yes. Through the WHO collaborative registration procedure, participating regulators rely on WHO assessment and inspection reports and aim to decide within 90 working days of receiving the full file.

What documents should I request from a supplier first?

Start with the GMP certificate, a WHO-format COPP, recent batch CoAs, Zone IVb stability data and confirmation that the dossier is in CTD format. These five documents tell you quickly whether a supplier can support registration and tenders.

Pharmaceutical Sourcing for Africa: A Buyer's Guide to Medicines, APIs and CDMO Services (2026)

Where Africa's medicines come from

What African buyers typically source